These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 18566455)

  • 1. Intersession repeatability of visual acuity scores in age-related macular degeneration.
    Patel PJ; Chen FK; Rubin GS; Tufail A
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4347-52. PubMed ID: 18566455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intersession repeatability of contrast sensitivity scores in age-related macular degeneration.
    Patel PJ; Chen FK; Rubin GS; Tufail A
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2621-5. PubMed ID: 19218618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Test-retest variability of reading performance metrics using MNREAD in patients with age-related macular degeneration.
    Patel PJ; Chen FK; Da Cruz L; Rubin GS; Tufail A
    Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3854-9. PubMed ID: 21421873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV; Steén B; Seregard S; Kvanta A
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration.
    Unver YB; Yavuz GA; Bekiroğlu N; Presti P; Li W; Sinclair SH
    Eye (Lond); 2009 Feb; 23(2):453-60. PubMed ID: 19039333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab for neovascular age-related macular degeneration in China.
    Li X; Hu Y; Sun X; Zhang J; Zhang M;
    Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
    Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM
    Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
    Retina; 2006; 26(9):994-8. PubMed ID: 17151485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
    Retina; 2007; 27(4):439-44. PubMed ID: 17420695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Subramanian ML; Ness S; Abedi G; Ahmed E; Daly M; Feinberg E; Bhatia S; Patel P; Nguyen M; Houranieh A
    Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.
    Moshfeghi AA; Rosenfeld PJ; Puliafito CA; Michels S; Marcus EN; Lenchus JD; Venkatraman AS
    Ophthalmology; 2006 Nov; 113(11):2002.e1-12. PubMed ID: 17027972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial.
    Subramanian ML; Abedi G; Ness S; Ahmed E; Fenberg M; Daly MK; Houranieh A; Feinberg EB
    Eye (Lond); 2010 Nov; 24(11):1708-15. PubMed ID: 20885427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.